The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia

E. J. Ayres, J. M. Hoeg, Kent R Bailey, J. G. Bieri

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.

Original languageEnglish (US)
Pages (from-to)325-331
Number of pages7
JournalDrug-Nutrient Interactions
Volume4
Issue number4
StatePublished - 1986
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
Neomycin
Tocopherols
alpha-Tocopherol
Placebos
Controlled Clinical Trials
Diet
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia. / Ayres, E. J.; Hoeg, J. M.; Bailey, Kent R; Bieri, J. G.

In: Drug-Nutrient Interactions, Vol. 4, No. 4, 1986, p. 325-331.

Research output: Contribution to journalArticle

@article{0db403cab1034c9f9edf596364fb82c8,
title = "The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia",
abstract = "Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.",
author = "Ayres, {E. J.} and Hoeg, {J. M.} and Bailey, {Kent R} and Bieri, {J. G.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "325--331",
journal = "Drug-Nutrient Interactions",
issn = "0272-3530",
number = "4",

}

TY - JOUR

T1 - The effect of neomycin on plasma alpha tocopherol levels in type II hyperlipoproteinemia

AU - Ayres, E. J.

AU - Hoeg, J. M.

AU - Bailey, Kent R

AU - Bieri, J. G.

PY - 1986

Y1 - 1986

N2 - Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.

AB - Use of oral neomycin as a hypocholesterolemic agent was found to decrease plasma alpha tocopherol levels during a 9-month, randomized, crossover placebo-controlled clinical trial with controlled diet. Pooled data from each treatment sequence showed a placebo α-tocopherol level of 1,896 ± 643 μg/dl, and a neomycin α-tocopherol concentration of 1,449 ± 451 μg/dl (p < .01). When all subjects were on neomycin simultaneously, the level increased to 1,665 ± 614 μg/dl (p < .05 from placebo). Normal plasma α-tocopherol ranges from 400-1,000 μg/dl. Neomycin treatment reduces but does not normalize elevated levels of α-tocopherol found in Type II hyperlipoproteinemia.

UR - http://www.scopus.com/inward/record.url?scp=0023032460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023032460&partnerID=8YFLogxK

M3 - Article

C2 - 3792214

AN - SCOPUS:0023032460

VL - 4

SP - 325

EP - 331

JO - Drug-Nutrient Interactions

JF - Drug-Nutrient Interactions

SN - 0272-3530

IS - 4

ER -